February 06, 2025

Bicistronic CAR T-Cell Therapy Demonstrates Clinical Activity in Relapsed or Refractory B-Cell ALL

A novel bicistronic CD19/CD22-directed CAR T-cell therapy (B019) has demonstrated high remission rates, durable responses, and a favorable safety profile among children with relapsed or refractory B-c...

The ASCO Post

March 28, 2024

Eflornithine for Adult and Pediatric Patients With High-Risk Neuroblastoma

On December 13, 2023, eflornithine (Iwilfin), an ornithine decarboxylase inhibitor, was approved for adult and pediatric patients with high-risk neuroblastoma with at least a partial response to prior...

The ASCO Post

May 05, 2023

Limited Surgery Plus Proton Therapy in Pediatric and Adolescent Patients With Craniopharyngioma

In a phase II trial (RT2CR) reported in The Lancet Oncology, Thomas E. Merchant, DO, and colleagues found that limited surgery plus proton therapy was associated with a high rate of disease control an...

The ASCO Post

September 15, 2023

Dana-Farber Research Publication 09.15.2023

This twice-monthly newsletter highlights the research endeavors at Dana-Farber Cancer Institute, noting recently published papers available from PubMed where Dana-Farber faculty are listed as first or senior authors.

Dana-Farber

February 08, 2023

Imaging Gets Boost From AI

Two very different populations are the latest to benefit from collaborations with the Biomedical Imaging Research Institute at Cedars-Sinai: children with a cancer predisposition syndrome called neurofibromatosis and men with prostate cancer.

Cedars-Sinai Pulse

June 25, 2024

Tovorafenib in Relapsed or Refractory BRAF-Altered Pediatric Low-Grade Glioma

U.S. FDA accelerates approval for tovorafenib (Ojemda) to treat pediatric low-grade glioma harboring a BRAF fusion or rearrangement or BRAF V600 mutation, providing a promising therapeutic option for these patients. Learn more at (source).

The ASCO Post

January 24, 2023

More Than 120 Dana-Farber Affiliated Faculty Named as 2023 Top Doctors in Boston Magazine

Boston magazine has named more than 120 physicians affiliated with Dana-Farber Cancer Institute to its annual "Top Doctors" guide.

Dana-Farber

January 26, 2023

Faculty Publications: Jan. 19 - Jan. 26

This week’s edition of Faculty Publications includes Cedars-Sinai studies that were published Jan.19 - Jan. 26.

Cedars-Sinai Pulse

August 08, 2023

Preoperative Chemoradiation With or Without Pazopanib in Nonrhabdomyosarcoma Soft-Tissue Sarcoma

As reported in the Journal of Clinical Oncology by Aaron R. Weiss, DO, and colleagues, follow-up in the Children’s Oncology Group/NRG Oncology phase II ARST1321 trial showed no differences in survival...

The ASCO Post